ImpediMed (ASX:IPD) - Managing Director & CEO, Rick Carreon
Managing Director & CEO, Rick Carreon
Sourced: The Courier Mail
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ImpediMed (IPD) has announced that NSW Health is expanding its use of the SOZO Digital Health Platform for lymphoedema prevention
  • NSW Health will be buying up to eight extra SOZO devices to help grow its lymphoedema prevention program for cancer patients
  • SOZO assesses patients with secondary lymphoedema to deliver a precise reading of fluid status and tissue composition in less than 30 seconds
  • The aim of the program is to help educate healthcare workers and patients about the condition
  • It is hoped that by with the correct tools, lymphoedema can be detected and controlled before it spreads and becomes worse
  • ImpediMed shares are steady and are currently trading for 3.8 cents each

ImpediMed (IPD) has announced that NSW Health is expanding its use of the SOZO Digital Health Platform for lymphoedema prevention.

NSW Health will be buying up to eight extra SOZO devices to help grow its lymphoedema (swelling in the arms and legs) prevention program for cancer patients.

Once the devices have been purchased, NSW Health will more than double the number of SOZO devices it currently has for the program. Five of the eight will be sent to the Western NSW Local Health District (LHD) of NSW Health.

“The SOZO technology and lymphoedema prevention model-of-care aligns well with our goals of improving patient care while decreasing costs associated with chronic lymphoedema treatment,” Director of Cancer Services and Innovation for Western NSW LHD of NSW Health, Ruth Jones commented.

“We have begun to see the benefits for patients using SOZO and, with these new devices, this will expand access to patients in a range of areas within the LHD,” she added.

SOZO assesses patients with secondary lymphoedema to deliver a precise reading of fluid status and tissue composition in less than 30 seconds.

A single SOZO reading allows clinicians across multiple specialities to provide individualised, proactive care that can help improve patient outcomes.

The aim of the lymphoedema prevention program is to help educate healthcare workers and patients about the condition. It is hoped that by with the correct tools, lymphoedema can be detected and controlled before it spreads and becomes worse.

“The experience at New South Wales Health demonstrates a successful approach for building lymphoedema prevention programs,” Managing Director and CEO Richard Carreon stated.

“By beginning at a small number of select sites, they were able to establish a robust program from which to expand across the health system. Now, fewer patients will have to endure the pain and hardship of living with chronic lymphoedema as well as its high cost treatments,” he said.

ImpediMed is steady on the market and shares are trading for 3.8 cents each at 3:56 pm AEST.

IPD by the numbers
More From The Market Herald
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.